PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
Rhea-AI Summary
PolyPid (Nasdaq: PYPD) signed an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada for prevention of surgical site infections. PolyPid will receive $15 million upfront at signing and a further $15 million upon expected FDA acceptance of the NDA in August 2026, plus eligibility for up to approximately $300 million in additional regulatory, development, and sales-based milestones.
Upon commercialization, PolyPid will manufacture and supply D-PLEX100 to Azurity for a transfer price and receive tiered royalties from mid-teen to mid-twenties percentages. Azurity may fund additional clinical programs for label expansion in North America. PolyPid retains commercial rights outside the U.S. and Canada and full ownership of its PLEX and Kynatrix platforms. The deal follows positive Phase 3 SHIELD II data, including achievement of the primary endpoint and a 60% relative risk reduction at a key secondary endpoint, with a U.S. launch targeted for Q1 2027.
Positive
- Over $320 million total economics including ~$30 million near term and up to ~$300 million in milestones
- $15 million upfront at signing plus $15 million upon anticipated FDA NDA acceptance in August 2026
- Tiered royalties on Azurity sales in U.S. and Canada from mid-teen to mid-twenties percentages
- Azurity-funded potential clinical development for label expansion into additional SSI indications in North America
- Positive Phase 3 SHIELD II results with 60% relative risk reduction in SSI incidence after abdominal colorectal surgery
- Retained global rights to D-PLEX100 outside U.S./Canada and full ownership of PLEX and Kynatrix platforms
Negative
- Milestone-heavy structure with up to ~$300 million contingent on future regulatory, development, and sales achievements
- Regulatory timing risk as NDA acceptance is expected, not yet confirmed, and launch is targeted for Q1 2027
- Regional commercialization limited as Azurity controls D-PLEX100 commercial rights in the U.S. and Canada
Market reaction: PYPD -27.38% on D-PLEX100 commercial partnership
On the day this news was published, PYPD declined 27.38%, reflecting a significant negative market reaction. Argus tracked a peak move of +4.8% during that session. Argus tracked a trough of -34.3% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $37M from the company's valuation, bringing the market cap to $98.75M at that time. Trading volume was exceptionally heavy at 8.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | NDA submission | Positive | +7.4% | Completed rolling FDA submission for D-PLEX100 supported by Phase 3 results |
| May 20 | Investor conference | Neutral | +4.0% | Management scheduled investor meetings at the Craig-Hallum institutional conference |
| May 13 | Q1 earnings | Negative | -7.5% | Reported quarterly loss and cash balance alongside regulatory and partnership updates |
| May 06 | Earnings scheduling | Neutral | -0.4% | Scheduled first-quarter financial results and operational highlights release |
| Apr 28 | Phase 3 data | Positive | -3.3% | Presented reduced severity of surgical site infections in SHIELD II analysis |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: the NDA submission and investor conference announcements were followed by gains of 7.42% and 3.99%, while clinical data was followed by a -3.28% move.
Key Terms
new drug application regulatory
breakthrough therapy designation regulatory
relative risk reduction medical
tiered royalties financial
active pharmaceutical ingredients technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- PolyPid to potentially receive over
$320 million in upfront and milestone payments, including$30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages - Azurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100
- Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgery
- Partnership follows positive Phase 3 SHIELD II results, demonstrating achievement of the primary endpoint and a
60% relative risk reduction at the secondary endpoint in SSI incidence, with PolyPid’s NDA submission to the FDA recently completed - U.S. launch targeted for the first quarter of 2027
PETACH TIKVA, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the “Agreement”) with Azurity Pharmaceuticals (“Azurity”), a privately held specialty pharmaceutical company, for the commercialization of D-PLEX100 in the United States and Canada for the prevention of surgical site infections (“SSIs”).
Under the terms of the Agreement, PolyPid will receive an upfront payment of
In addition to the upfront and milestone payments, as part of the collaboration, the parties may agree to jointly pursue potential label expansion of D-PLEX₁₀₀ in the U.S. and Canada into additional SSI indications beyond abdominal, with Azurity providing funding for these additional clinical development programs. PolyPid will retain global commercial rights to D-PLEX100 outside of the U.S. and Canada, manufacturing rights worldwide, and full ownership of its PLEX platform, Kynatrix™ technology and associated pipeline assets.
“This partnership is a defining step in PolyPid’s transition into a commercial-stage company, and Azurity is the right partner to bring D-PLEX100 to U.S. and Canadian patients, hospitals and surgeons,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “We believe that Azurity’s first-in-class commercial model and demonstrated commercial execution will be invaluable in expanding access to D-PLEX100, if approved. Importantly, this collaboration represents a meaningful validation of our unique platform, and allows us to fully realize the U.S. and Canadian commercial value of D-PLEX100 while putting us in a position of financial strength to continue investing in our Kynatrix technology, pipeline, and the next generation of therapies.”
“At Azurity, we believe meaningful innovation is measured by the difference a therapy makes in the realities of patient care,” said Ronald Scarboro, Chief Executive Officer of Azurity Pharmaceuticals. “D-PLEX100 is a differentiated therapy addressing an important unmet need, and we are excited to partner with PolyPid to help bring it to patients in the United States and Canada, if approved. Our commercial model was built to support specialized therapies like this - connecting the right treatment to the right healthcare professionals and patients through efficient, focused execution. Together, we believe we can expand access to an important new option while exploring opportunities to broaden its impact in the years ahead.”
About D-PLEX100
D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site with the goal of preventing abdominal surgical site infections (“SSIs”). Following the administration of D-PLEX100 into the surgical site, PolyPid’s delivery technology, Kynatrix, is designed to pair with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. In the Phase 3 SHIELD II trial, D-PLEX100 recently demonstrated positive results in achieving its primary end point and a
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
About Azurity Pharmaceuticals
Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to redefining medicine for the real world. Azurity’s first-in-class enterprise model challenges the status quo by rethinking how therapies are designed, delivered, and accessed. With more than 50 medicines across 10 therapeutic areas, Azurity’s mission is fueled by a growing portfolio that reaches millions of people in more than 50 countries. Learn more at www.azurity.com
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company and Azurity are using forward-looking statements when discussing the potential benefits, terms and structure of the exclusive commercial partnership between PolyPid and Azurity; the timing, receipt and amount of upfront, regulatory, development and sales-based milestone payments and royalties; the timing of FDA acceptance and potential approval of the NDA for D-PLEX100; the anticipated timing of a U.S. commercial launch of D-PLEX100, including the target of the first quarter of 2027; the potential for label expansion of D-PLEX100 into indications beyond abdominal colorectal surgery and the funding of related clinical development; the ability to successfully commercialize D-PLEX100, if approved, in the U.S. and Canada; the therapeutic and commercial potential of D-PLEX100, including its ability to reduce the incidence of SSIs and that D-PLEX100 is a differentiated therapy addressing an important unmet need. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company and Azurity assume no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company or Azurity do update one or more forward-looking statements, no inference should be drawn that the Company or Azurity will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid and Azurity are not responsible for the contents of third-party websites.
PolyPid Investor Relations and Media Contacts
Ori Warshavsky
908-858-5995
IR@Polypid.com
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com
Azurity Pharmaceuticals Media Contacts
Media Relations
media@azurity.com
